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Aminocaproic acid is a synthetic mono-
amino carboxylic acid, which is com-
monly used for the treatment of
bleeding disorders owing to its anti-
fibrinolytic activity.
Case Report
A 47-year-old Caucasian woman had
a pruriginous dermatitis involving her
axillary, infra-mammary and inguinal
flexures, and the lateral aspects of her
trunk. Confluent erythematous patches
without epidermal detachment were
observed, sparing the extremities and
mucous membranes (Fig. 1). There
were no systemic symptoms.
A week before the onset of dermati-
tis, she was started on aminocaproic
acid treatment (9 g/day) for exces-
sive vaginal bleeding due to uterine
myomatosis. The drug was promptly
withdrawn when the cutaneous lesions
appeared. The patient was not on any
other systemic or topical formulations.
Complete remission of the skin lesions
was achieved with oral antihistamines,
topical corticosteroids, and emollients.
Patch tests were performed 6 weeks
after resolution of the lesions. Finn®
chambers on Scanpor® tape were used
and readings were made at D2 and
D3 in accordance with the International
Contact Dermatitis Research Group
(ICDRG) criteria. Aminocaproic acid
(30% pet. Epsicaprom®, Bial®, Portu-
gal) showed a strongly positive reac-
tion (+++).
Aminocaproic acid diluted to a 1%
aqueous solution (Bial®, Portugal) eli-
cited a reaction (+) at D2 and D3,
but both 5% aqueous and 10% aqueous
aminocaproic acid elicited strong pos-
itive reactions at D3 (++ and +++,
respectively; Fig. 2). The Portuguese
baseline series was also applied but
no further positive reactions were seen.
Epsicaprom® (30% pet.) patch test-
ing elicited no reactions in 10 healthy
controls.
Discussion
Previously, the appearance of eyelid
eczema due to aminocaproic acid has
been reported in Japan, where it is often
used in eye drops (1, 2). However,
generalized cutaneous reactions to sys-




aminocaproic acid ingestion have been
reported (3, 4). Here, the diagnoses
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Fig. 1. Confluent erythematous patches involving the axillary, inframammary and
inguinal flexures and the lateral aspects of the trunk.
Fig. 2. Patch tests with Aminocaproic acid diluted to 1%, 5% and 10% aqueous
solutions (D3).
were supported by patch testing, where-
as in the former they were made tak-
ing 0.8 g of aminocaproic acid. Further
cases of adverse cutaneous reactions
to aminocaproic acid include rare sys-
temic reactions in which the diagno-
sis was based purely on clinical data
without patch testing (5). Our report
represents an unusual case of a gen-
eralized cutaneous reaction to systemic
aminocaproic acid in which the diag-
nosis was supported by patch tests.
References
1. Tanaka M, Nizeki H, Miyakawa S I.
Contact dermatitis from epsilon-
aminocaproic acid. Contact Dermatitis
1993: 28: 124.
2. Miyamoto H, Okajima M. Allergic
contact dermatitis from epsilon-
aminocaproic acid. Contact Dermatitis
2000: 43: 50.
3. Gutie´rrez M, Lo´pez M, Ruı´z M. Posi-
tivity of patch tests in cutaneous reac-
tion to aminocaproic acid: two case
reports. Allergy 1995: 50: 745–746.
4. Villareal O. Systemic dermatitis
with eosinophilia due to epsilon-
aminocaproic acid. Contact Dermatitis
1999: 40: 114.
5. Brooke C P, Spiers E M, Omura E F.
Noninflammatory bullae associated
with epsilon-aminocaproic acid infu-




Hospital de Curry Cabral
Rua da Beneficeˆncia 8
1069-166 Lisboa
Portugal
Tel/Fax: +351-217924274
e-mail: danielaccunha@gmail.com

